Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Introduction
00:00 • 2min
The FDA Is Too Cautious, but Should It Be Doing Something Differently?
02:10 • 5min
The FDA's Precautionary Approach to Drug Approval
07:03 • 5min
Is the FDA Too Conscious?
12:08 • 2min
The FDA's Level of Caution
13:45 • 2min
The Future of Medicine
15:27 • 2min
The Pressure on the FDA to Approve Drugs
17:11 • 2min
The Future of Drug Regulation
19:23 • 3min
The Importance of Real World Studies in the FDA's Operations
22:10 • 5min
The Standard Is What It Is
27:18 • 2min
The FDA Is Not Keeping Up With the Possibilities, Is Not Evolving, and Is Using Outdated Methods
29:36 • 2min
The FDA's Response to Pressure
31:07 • 2min
The FDA's Accelerated Approval of the Alzheimer Drug
33:04 • 3min
The Importance of Broadening the Aperture
36:22 • 3min
The Importance of Accelerated Approval in Drug Development
39:10 • 4min
The Importance of Data in Drug Approval
43:33 • 4min
Combining Extreme Polarization Through Civil and Respectful Debate
47:46 • 2min